“Only unfortunate thing is we may get our covid19 trial results before the uplist.”
Exactly.
At this time, the SP and the amount of cash the company has on hand is not the determining factor to uplist on the NASDAQ; the pending COVID trial results are.
If the data from either the M2M or severe trial can even be interpreted as not good, then the stock will pull back to the $1-2 range and uplisting will not be possible. I believe CYDY will be required to conduct a larger phase 3 for the M2M trial (unless the data is unequivacbly great) and I’m unsure how the SP will respond to that. Investors should be aware that those who short stocks will immediately go after the small trial size of 75, regardless of the data is good, and use that number to sow doubt.
Basically, uplisting is dependent on the outcome of the trials.
Exactly.
At this time, the SP and the amount of cash the company has on hand is not the determining factor to uplist on the NASDAQ; the pending COVID trial results are.
If the data from either the M2M or severe trial can even be interpreted as not good, then the stock will pull back to the $1-2 range and uplisting will not be possible. I believe CYDY will be required to conduct a larger phase 3 for the M2M trial (unless the data is unequivacbly great) and I’m unsure how the SP will respond to that. Investors should be aware that those who short stocks will immediately go after the small trial size of 75, regardless of the data is good, and use that number to sow doubt.
Basically, uplisting is dependent on the outcome of the trials.
3
1
